Endologix Appoints Vice President of Quality
September 22 2008 - 4:00AM
Business Wire
Endologix, Inc. (Nasdaq: ELGX), developer of the Powerlink� System
for the minimally invasive treatment of abdominal aortic aneurysms
(AAA), announces the expansion of its management team with the
appointment of Gary I. Sorsher as Vice President, Quality,
effective October 1, 2008. Mr. Sorsher brings 20 years of quality
assurance experience, including the past 15 years in medical
devices with Bard Peripheral Vascular and Cordis, a Johnson &
Johnson Company. �We are adding another experienced industry
veteran to our management team to provide additional depth and
leadership to support our growth,� said John McDermott, Endologix
President and Chief Executive Officer. �Gary has developed and
implemented effective quality and risk management systems both
domestically and internationally, and has a proven track record for
successfully introducing new products in the vascular market. He
has a strong technical background and a hands-on leadership style
that will be an exceptional fit with Endologix.� Most recently, Mr.
Sorsher served for two years as Director of Quality Engineering at
Bard Peripheral Vascular, where he oversaw quality assurance
operations for Bard Peripheral Vascular and Bard Biopsy Systems.
Prior to that, he spent 13 years at Cordis, a Johnson & Johnson
Company holding several positions with increasing responsibility
during his tenure. As Director of Quality Assurance � New Product
Development, he provided technical and strategic guidance to global
engineering teams to facilitate timely and cost-effective
deployment of robust designs and processes. He also served as the
senior quality assurance representative for Cordis� Global
Commercialization Team responsible for drug eluting stents, stent
delivery systems and angioplasty products. Mr. Sorsher received a
Master of Science and Bachelor of Science in electrical engineering
from Byelorussian Polytechnic Institute, USSR. About Endologix
Endologix, Inc. develops and manufactures minimally invasive
treatments for vascular diseases. Endologix�s Powerlink System is
an endovascular stent graft for treating abdominal aortic aneurysms
(AAA). AAA is a weakening of the wall of the aorta, the largest
artery in the body, resulting in a balloon-like enlargement. Once
AAA develops, it continues to enlarge and, if left untreated,
becomes increasingly susceptible to rupture. The overall patient
mortality rate for ruptured AAA is approximately 75%, making it a
leading cause of death in the U.S. Additional information can be
found on Endologix�s Web site at www.endologix.com.
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Endologix (NASDAQ:ELGX)
Historical Stock Chart
From Jul 2023 to Jul 2024